One of the authors of a shocking new study suggesting abortion pill complications are 22 times higher than reported on the U.S. Food and Drug Administration (FDA)-approved drug label is calling on the agency to use real-world data to conduct its own research.
A study from the Ethics and Public Policy Center (EPPC) released at the end of April found that 10.93 percent of women who had mifepristone abortions — the first drug used in a two-drug medication abortion regimen — experienced severe complications including sepsis, infection, hemorrhaging, or another serious adverse event within 45 days following the abortion. This percentage is significantly higher than the less than 0.5 percent in clinical trials reported on the FDA-approved drug label.
The study is based on analysis
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!